Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL)

Jessica C. Hochberg, MD, Stanton Goldman, MD, Matthew J. Barth, MD, Qiuhu Shi, PhD, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Jackie Basso, Yaya Chu, PhD, Humayun Islam, Perry Gerard, MD MBA, FACR, Javier Oesterheld, MD, Kenneth Matthew Heym, MD, Ivan I. Kirov, MD, Richard A. Drachtman, MD, Paul Harker-Murray, MD PhD, Sherrie L. Perkins, MD PhD, Rodney R. Miles, MD PhD, Bruce Shiramizu, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-139464

Published: 2020

Journal Articles

Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-g Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449)

Allyson M. Flower, MD, Rachel Friedmann, DO, Janet Ayello, MS, MT(ASCP), Olivia Rigot, PhD, Lauren Harrison, RN, MSN, Erin Morris, RN, BSN, Meghan Sturhahn, RN, MSN, Elana Maryamchik, MD, Yongping Wang, MD, Lynn O'Donnell, PhD, Rolla Abu-Arja, MD, Dean Anthony Lee, MD PhD, Julie-An Talano, MD, Bryon Johnson, PhD, Nancy Bunin, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140834

Published: 2020

Journal Articles

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Jessica C. Hochberg, MD, Jaclyn Basso, RN, MSN, PNP, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Allyson M. Flower, MD, Aliza Gardenswartz, MD, Qiuhu Shi, PhD, Perry Gerard, MD MBA, FACR, Humayan Islam, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 127.

https://doi.org/10.1182/blood-2019-128684

Published: 2019

Journal Articles

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Anthony N. Audino, MD, Matthew J. Barth, MD, Aradhana Tiwari, PhD, Dina Edani, MS, Janet Ayello, MS, MT(ASCP), Lauren Harrison, RN, MSN, Erin Morris, RN, BSN, Jessica C. Hochberg, MD, Stanton Goldman, MD, Christian Klein, PhD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 3963.

https://doi.org/10.1182/blood-2019-128580

Published: 2019

Journal Articles

Upfront Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Jessica C. Hochberg, MD, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Allyson M. Flower, MD, Quihu Shi, PhD, Jaclyn Basso, RN, MSN, PNP, Mitchell S. Cairo, MD

Blood (2017) 130 (Supplement 1): 4094.

https://doi.org/10.1182/blood.V130.Suppl_1.4094.4094

Published: 2017

Journal Articles

Mitoxantrone in Combination with Clofarabine (MITCL) in Children, Adolescents and Young Adults with Refractory/Relapsed Acute Leukemia

Jessica C. Hochberg, MD, Javier Oesterheld, MD, Allyson M. Flower, MD, Liana Klejmont, Pharm D, Gregory Hemenway, MS2, Lauren Harrison, RN, MSN, Qiuhu Shi, PhD, Mitchell S. Cairo, MD

Blood (2017) 130 (Supplement 1): 3893.

https://doi.org/10.1182/blood.V130.Suppl_1.3893.3893

Published: 2017

Journal Articles

A Pilot Trial of Unmatched Human Placenta-Derived Stem Cells (HPDSCs) in Conjunction with Unrelated Cord Blood Transplantation (UCBT) in Children and Young Adults with Malignant and Non-Malignant Disease (IND 14949)

Blood (2016) 128 (22): 4671.

https://doi.org/10.1182/blood.V128.22.4671.4671

Published: 2016

Journal Articles

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Timmy O'Connell, MS, Lauren Harrison, RN, MSN, Carmella van de Ven, MA, Matthew J. Barth, MD, Rodney R. Miles, MD PhD, Paul J. Galardy, MD, Stanton Goldman, MD, Megan S Lim, MD PhD, Michelle L. Hermiston, MD PhD, Linda McAllister-Lucas, MDPhD, Lisa Giulino-Roth, MD, Sherrie L. Perkins, MD PhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 5117.

https://doi.org/10.1182/blood.V126.23.5117.5117

Published: 2015

Journal Articles

Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Lauren Harrison, RN, MSN, Carmella van de Ven, MA, Matthew J. Barth, MD, Rodney R. Miles, MD PhD, Paul J. Galardy, MD, Stanton Goldman, MD, Megan S Lim, MD PhD, Michelle L. Hermiston, MD PhD, Linda McAllister-Lucas, MDPhD, Lisa Giulino-Roth, MD, Sherrie L. Perkins, MD PhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 4852.

https://doi.org/10.1182/blood.V126.23.4852.4852

Published: 2015

Journal Articles

A Pilot Study of Mitoxantrone in Combination with Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) with Refractory/Relapsed Acute Leukemia

Jessica C. Hochberg, MD, Javier Oesterheld, MD, Olga Miitano, PharmD, Lauren Harrison, RN, MSN, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 2499.

https://doi.org/10.1182/blood.V126.23.2499.2499

Published: 2015

Journal Articles

Genomic Pathways and Potential Therapeutic Targets in Pediatric Burkitt Lymphoma (PBL): A Children's Oncology Group Report

Mitchell S. Cairo, MD, Nancy Day, Ph.D., Stanton Goldman, MD, Warren G. Sanger, PhD, Lauren Harrison, RN, MSN, Megan S. Lim, MD, PhD, Rodney R. Miles, MD, PhD, Sherrie L. Perkins, MD, PhD

Blood (2011) 118 (21): 1587.

https://doi.org/10.1182/blood.V118.21.1587.1587

Published: 2011

Journal Articles

Safety of Liposomal Cytarabine Prophylaxis in Pediatric Bone Marrow Transplant (BMT) Recipients with Acute Leukemia (AL) and Non Hodgkin Lymphoma (NHL) At High Risk of CNS Relapse

Jessica Hochberg, MD, Deirdre Duffy, BS, Lauren Harrison, RN, MSN, Erin Morris, RN, Mitchell S. Cairo, MD

Blood (2011) 118 (21): 4249.

https://doi.org/10.1182/blood.V118.21.4249.4249

Published: 2011

Journal Articles

The Efficacy of Rasburicase and Rituximab Combined with FAB Chemotherapy in Children and Adolescents with Newly Diagnosed Stage III/IV, BM+ and CNS+ Mature B-NHL: A Children's Oncology Group Report

Stanton Goldman, MD, Paul J. Galardy, MD, Lynette Smith, MS, Sherrie L. Perkins, MD, PhD, Bruce Shiramizu, MD, Thomas Gross, MD, PhD, Warren G. Sanger, PhD, Lauren Harrison, RN, MSN, Mitchell S. Cairo, MD

Blood (2011) 118 (21): 2702.

https://doi.org/10.1182/blood.V118.21.2702.2702

Published: 2011

Journal Articles

Reduced-Toxicity (RTC) Versus Myeloablative Conditioning (MAC) Prior to Allogeneic Stem Cell Transplantation in Pediatric Participants: Significant Improvement in Physical Functioning Following RTC Versus MAC

Jennifer A Oberg, EdD, Erin Morris, RN, Lauren Harrison, RN, MSN, Julia Glade Bender, MD, James H Garvin, Jr., MD, PhD, Stephen Sands, PsyD, Mitchell S. Cairo, MD

Blood (2011) 118 (21): 2069.

https://doi.org/10.1182/blood.V118.21.2069.2069

Published: 2011

Journal Articles

Comparative Genomic Identification of Unique Signal Transduction Pathways and Targets In Pediatric Burkitt Lymphoma (PBL)

Nancy S Day, PhD, Janet Ayello, MS, MT(ASCP), Ian Waxman, MD, Carmella van de Ven, MA, Megan S. Lim, MD, PhD, Sherrie L. Perkins, MD, PhD, Warren G. Sanger, PhD, Lauren Harrison, RN, MSN, Stan Goldman, MD, Mitchell S. Cairo, MD

Blood (2010) 116 (21): 631.

https://doi.org/10.1182/blood.V116.21.631.631

Published: 2010

Journal Articles

Dose Escalation of Clofarabine In Combination with Cytarabine and Total Body Irradiation (TBI) Followed by Allogeneic Stem Cell Transplantation (AlloSCT) In Children, Adolescents and Young Adults (CAYA) with Poor-Risk Acute Leukemia

Mark B Geyer, AB, Angela M Ricci, BA, Lauren Harrison, RN, MSN, Deirdre Duffy, BS, Monica Bhatia, MD, James H Garvin, Jr., MD, Diane George, MD, Prakash Satwani, MD, Alexandra C Cheerva, MD, MS, Julie Talano, MD, Fevzi Ozkaynak, MD, Theodore B. Moore, MD, MS, Joseph Schwartz, MD, Lee Ann Baxter-Lowe, PhD, Mitchell S. Cairo, MD

Blood (2010) 116 (21): 36.

https://doi.org/10.1182/blood.V116.21.36.36

Published: 2010

Journal Articles

Preliminary Results of the Addition of Rasburicase to the Reduction Cycle and Rituximab to the Induction and Consolidation Cycles of FAB Group C Chemotherapy in Children and Adolescents with Advanced Stage (Bone Marrow ±CNS) Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report.

Stanton Goldman, MD, James Lynch, PhD, Lauren Harrison, RN, Thomas Gross, MD, PhD, Bruce Shiramizu, MD, Warren Sanger, PhD, Sherrie L. Perkins, MD, PhD, Mitchell S. Cairo, MD

Blood (2009) 114 (22): 104.

https://doi.org/10.1182/blood.V114.22.104.104

Published: 2009

Journal Articles

DLEU1 siRNA Gene Knockdown IN BURKITT LYMPHOMA (bl) IS ASSOCIATED with A SIGNIFICANT Decrease IN Cyclophosphamide (CY) and/or Rituximab Induced Apoptosis: Mechanism of Drug Resistance in BL.

Nancy Day, Ph.D., Janet Ayello, MS, MT, Carmella van de Ven, MA, Megan S Lim, MD, PhD, Sherrie L. Perkins, MD, PhD, Warren Sanger, PhD, Lauren Harrison, RN, Stanton Goldman, MD, Mitchell S. Cairo, MD

Blood (2009) 114 (22): 1928.

https://doi.org/10.1182/blood.V114.22.1928.1928

Published: 2009

Journal Articles

Reduced Toxicity Conditioning (RTC) Compared to Myeloablative Conditioning (MAC) Prior to Unrelated Cord Blood Transplantation (UCBT) in Pediatric Recipients Was Associated with Similar but Also Delayed Time to Immune Reconstitution and a Concomitant Significant Decrease in Grade II-IV Agvhd.

Jason Freedman, M.D., Diane George, MD, Judith Jacobson, DrPH, MBA, Mark Geyer, AB, Carmella van de Ven, MA, Nathifa Fearon, RN, MSN, Claire Fanelli, RN, BSN, Bradford Tallamy, BA, Prakash Satwani, MD, Monica Bhatia, MD, James H. Garvin, Jr., MD, M. Brigid Bradley, MD, Tracey Schonfeld, RN, BSN, Lauren Harrison, RN, Erin Morris, RN, Joseph Schwartz, MD, Lee Ann Baxter-Lowe, PhD, Mitchell S. Cairo, MD

Blood (2009) 114 (22): 2304.

https://doi.org/10.1182/blood.V114.22.2304.2304

Published: 2009

Journal Articles

Safety, Efficacy and Rituximab Levels Following Chemoimmunotherapy (Rituximab + FAB Chemotherapy) in Children and Adolescents with Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children’s Oncology Group Report

Mitchell S. Cairo, MD, James Lynch, PhD, Lauren Harrison, RN, Carmella van de Ven, MS, Thomas Gross, MD, PhD, Bruce Shiramizu, MD, Warren Sanger, PhD, Sherrie L. Perkins, MD, PhD, Stanton Goldman, MD

Blood (2008) 112 (11): 838.

https://doi.org/10.1182/blood.V112.11.838.838

Published: 2008

NARROW

Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL)

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Upfront Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Mitoxantrone in Combination with Clofarabine (MITCL) in Children, Adolescents and Young Adults with Refractory/Relapsed Acute Leukemia

A Pilot Trial of Unmatched Human Placenta-Derived Stem Cells (HPDSCs) in Conjunction with Unrelated Cord Blood Transplantation (UCBT) in Children and Young Adults with Malignant and Non-Malignant Disease (IND 14949)

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL

Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL

A Pilot Study of Mitoxantrone in Combination with Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) with Refractory/Relapsed Acute Leukemia

Genomic Pathways and Potential Therapeutic Targets in Pediatric Burkitt Lymphoma (PBL): A Children's Oncology Group Report

Safety of Liposomal Cytarabine Prophylaxis in Pediatric Bone Marrow Transplant (BMT) Recipients with Acute Leukemia (AL) and Non Hodgkin Lymphoma (NHL) At High Risk of CNS Relapse

The Efficacy of Rasburicase and Rituximab Combined with FAB Chemotherapy in Children and Adolescents with Newly Diagnosed Stage III/IV, BM+ and CNS+ Mature B-NHL: A Children's Oncology Group Report

Reduced-Toxicity (RTC) Versus Myeloablative Conditioning (MAC) Prior to Allogeneic Stem Cell Transplantation in Pediatric Participants: Significant Improvement in Physical Functioning Following RTC Versus MAC

Comparative Genomic Identification of Unique Signal Transduction Pathways and Targets In Pediatric Burkitt Lymphoma (PBL)

Dose Escalation of Clofarabine In Combination with Cytarabine and Total Body Irradiation (TBI) Followed by Allogeneic Stem Cell Transplantation (AlloSCT) In Children, Adolescents and Young Adults (CAYA) with Poor-Risk Acute Leukemia

DLEU1 siRNA Gene Knockdown IN BURKITT LYMPHOMA (bl) IS ASSOCIATED with A SIGNIFICANT Decrease IN Cyclophosphamide (CY) and/or Rituximab Induced Apoptosis: Mechanism of Drug Resistance in BL.

Reduced Toxicity Conditioning (RTC) Compared to Myeloablative Conditioning (MAC) Prior to Unrelated Cord Blood Transplantation (UCBT) in Pediatric Recipients Was Associated with Similar but Also Delayed Time to Immune Reconstitution and a Concomitant Significant Decrease in Grade II-IV Agvhd.

Safety, Efficacy and Rituximab Levels Following Chemoimmunotherapy (Rituximab + FAB Chemotherapy) in Children and Adolescents with Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children’s Oncology Group Report

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only